Juno Therapeutics (JUNO) Worth $110/Share in Takeover - Citi

January 17, 2018 8:09 AM EST Send to a Friend
Citi analyst Robyn Karnauskas weighed in on Juno Therapeutics (NASDAQ: JUNO) amid reports that Celgene (NASDAQ: CELG) is in talks ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login